ProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026
Globe Newswire•03/11/2026•07:00 ET
0
Key Highlights
- ➤ProMIS will report third-quarter 2026 financial results on November 12, 2026
- ➤Conference call and webcast scheduled for November 12 at 4:30 p.m. ET
- ➤PMN310 remains in Phase 1b development for Alzheimer’s disease
- ➤Investor Q&A outlines PMN310’s scientific rationale versus other amyloid-targeting approaches
Cambridge, Massachusetts, Nov. 03, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced it will report financial results for the third quarter ended September 30, 2026, and provide corporate updates on November 12, 2026. The company will host a conference call and webcast on the same day at 4:30 p.m. ET.
Dial-in:1-877-407-9208 (U.S. Investors) 1-201-493-6784 (International)
Get started
Create a free account to read the full story.